Esperion Therapeutics Inc. (ESPR) Stock: A Closer Look at the Market Potential
Company’s 36-month beta value is 0.88.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as
Company’s 36-month beta value is 0.88.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as
The stock of Esperion Therapeutics Inc. (NASDAQ: ESPR) has increased by 4.28 when compared to last closing price of 1.87. Despite this, the company has
The stock of Esperion Therapeutics Inc. (ESPR) has seen a -33.95% decrease in the past week, with a -2.28% drop in the past month, and
Esperion Therapeutics Inc. (NASDAQ: ESPR)’s stock price has gone rise by 4.18 in comparison to its previous close of 3.11, however, the company has experienced
Company’s 36-month beta value is 0.83.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.